|Year : 2019 | Volume
| Issue : 6 | Page : 715-729
A systematic review of standard treatment guidelines in India
Paresh Girdharlal Koli1, Nilima A Kshirsagar2, Yashashri C Shetty1, Dhvani Mehta3, Yashaswini Mittal3, Urwashi Parmar1
1 Department of Pharmacology & Therapeutics, Seth Gordhandas Sunderdas Medical College & King Edward Memorial Hospital, Mumbai, India
2 National Chair of Clinical Pharmacology, Indian Council of Medical Research, New Delhi, India
3 Vidhi Centre for Legal Policy, New Delhi, India
|Date of Submission||21-May-2018|
|Date of Web Publication||3-Sep-2019|
Dr Yashashri C Shetty
Department of Pharmacology & Therapeutics, 1st Floor, Main College Building, Seth GS Medical College & KEM Hospital, Parel, Mumbai 400 012, Maharashtra
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background & objectives: Standard treatment guidelines (STGs) are the cornerstone to therapeutics. Multiple agencies in India develop STGs. This systematic review was conducted to find out STGs available in India, evaluate if these were as per World Health Organization (WHO) recommendations for STGs and compare these with National Institute for Health and Care Excellence (NICE) guidelines. Information on legal authority and responsibility for formulating STGs was also sought.
Methods: PRISMA guidelines were followed. Publications from PubMed and Google Scholar were searched for STGs using terms 'Standard Treatment Guidelines AND India'. Data from STGs were compiled in excel as per the WHO and authors' criteria for STGs and compared with NICE guidelines.
Results: PubMed and Google Scholar search provided 56 publications (out of 1695 search results) mentioning 27 STGs. Google search and replies from authors led us 36 STGs, totalling to 63 STGs. No STG mentioned any specific period of revision, eight STGs were not evidence-based, 55 had some Indian references, 48 STGs were for single disease and the remaining multi-disease, three STGs did not include diagnostic criteria, 16 STGs did not give prescribing information of recommended treatment and 16 STGs provide no referral criteria for patients. Fifty five STGs did not mention level of health care. While NICE is a single legal authority in England and guidelines are as per WHO recommendations for STGs, in India although Acts and rules do not vest authority, National Health Systems Resource Center is generally designated responsible for STGs.
Interpretation & conclusions: In India, although there are multiple STGs developed by various authorities and professionals for the same conditions, these fulfil WHO recommendations only partially. Authority with statutory duty collaborating with professional organizations, a standard methodology for adopting international guidelines, Indian data for evidence base, attention to local needs will help in developing better STGs and their acceptance.
Keywords: Evidence-based guidelines - rational use of medicines - STGs therapeutic guidelines - treatment guidelines
|How to cite this article:|
Koli PG, Kshirsagar NA, Shetty YC, Mehta D, Mittal Y, Parmar U. A systematic review of standard treatment guidelines in India. Indian J Med Res 2019;149:715-29
|How to cite this URL:|
Koli PG, Kshirsagar NA, Shetty YC, Mehta D, Mittal Y, Parmar U. A systematic review of standard treatment guidelines in India. Indian J Med Res [serial online] 2019 [cited 2020 Jun 1];149:715-29. Available from: http://www.ijmr.org.in/text.asp?2019/149/6/715/265966
Providing quality healthcare to all is a key challenge for the Government of India. Standard treatment guidelines (STGs), alternatively known as standard treatment schedules, standard treatment protocols or therapeutic guidelines, are systematically developed statements which are designed to assist practitioners and patients in making informed decisions about suitable healthcare for specific clinical conditions. These include the preferred pharmaceutical and non-pharmaceutical treatments for common health problems came across by people in a specific health system. These STGs are used worldwide to prevent the misuse of medicines through the improper treatment of common problems and to encourage the economically efficient and therapeutically effective usage of medicines. The rising cost of healthcare, differences in clinical practice among providers and hospitals, and problems faced by prescribers in keeping themselves up-to-date with fast-growing new scientific evidence, especially in places with limited resources, have increased interest in, and the importance of STGs.
Experience and studies have shown that there could be ineffective, unsafe, or wasteful prescribing, even when the drugs supply is based on an approved formulary or essential medicines list. It is falsely believed that STGs bring constraints to prescribing. STGs only advise prescribers, who still retain the power and responsibility to make decisions about appropriate treatments for their patients, and define the boundaries between the accepted norms in treating a disease, based on clinical evidence and the practice of relying purely on clinical experience.
Sharma et al have noted that while some fruitful approaches to developing STGs have been well documented in India, multiple clinical practice guidelines continue to be produced by insurers, professional organizations, individuals, and others. While the quality of the STGs produced has not been assessed systematically, these are reported to be of poor quality or content or conflict with each other, failing to inspire confidence in prescribers. The development of STGs is a complex and lengthy process, and has its own risks. Because of their non-binding nature, there is a risk that these guidelines will not be accepted by clinicians,. The creation of effective guidelines needs robust development, strong editorial and project management processes, along with a keen eye for details about various sections of the guidelines.
The aim of this study was to conduct a systematic review of STGs available in India to evaluate if recommendations for STGs by World Health Organization (WHO) are fulfilled. The secondary objective was to compare the manner in which STGs are framed in India with more established processes in the UK and USA.
| Material & Methods|| |
Search strategy:The inclusion criteria were published articles in the English language which mentioned STGs in India. 'Standard Treatment Guidelines AND India' were the keywords used for the search strategy. A systematic literature search was conducted till March 2016, in two major databases namely, PubMed and Google Scholar. The PRISMA guidelines and Cochrane handbook for systematic reviews provided a framework for the reporting structure of this systematic review,. The focus of the search was to retrieve STGs mentioned in scholarly articles and in related Google searches. Google search was also done to find any relevant STGs which might not be found in published journal articles. Non-peer reviewed journals were also included in the search as many of the STGs in India are published on either government websites or non-peer reviewed journals. A manual search was also done in references list of the retrieved publications for other publications that might fulfil the study inclusion criteria. The authors of the shortlisted publications (whose emails were available in the publication or on the internet) were contacted by email to pursue their advice on other publications related to our research question, allowing one-month time for them to reply.
Screening process for inclusion: The results were restricted to studies on human subjects. Only STGs that were available online were included. At each stage, two independent reviewers assessed the publications for the inclusion criteria. Publications about non-Indian STGs were excluded.
Assessment of published reports/studies: The STGs obtained from the refined search were reviewed for analysis and to capture the information on the variables of interest (WHO and authors' criteria) in a spreadsheet. The extraction of data was done and entries were checked. Multiple STGs available from a single source were counted as a single STG and not as multiple.
The WHO criteria, were: condition for which the STG was developed, STG was for a single disease or multi-diseases, presence of diagnostic criteria, treatment objectives, non-drug treatment, drug/ treatment of choice, 2nd or 3rd line of treatment with indications. Prescribing information, patient referral criteria, patient education regarding the condition and the cost of treatments, especially if alternatives were proposed.
Authors' criteria were: name, year of publication, and edition of the STG, number of years after which STGs were revised, whether management algorithm was given, was the STG evidence-based, development authority of the STG, whether STG was part of a national programme and did the STG have specific guidelines for primary, secondary and tertiary levels.
In the Indian context, since the dose recommended (variation due to genetic and environmental factors, nutrition, and body weight) as well as the drug of choice (due to resistant microbes) may be different, evidence from Indian studies would be important. Hence, references were scrutinized and if all references were Indian studies, it was considered as entirely Indian evidence-based STG, and if references were Indian plus international studies, it was considered partially Indian evidence-based.
Methodology used for extracting information on the legal authority and responsibility for developing STGs: this information was retrieved by means of a Google search for terms such as 'STGs in India' and 'clinical guidelines in the UK'. In addition, the text of the Indian Clinical Establishments (Registration and Regulation) Act 2010 was scrutinized for its provisions on STGs. The websites of the National Health Mission (NHM) and National Institute for Health and Care Excellence (NICE) were surveyed to find out the authority vested with this responsibility and to understand how STGs in India and the UK are framed and disseminated,,,. Lastly, a number of decisions of courts in India and in the UK that were available on case law databases such as Manupatra and Westlaw, or were referred to in the journal articles were searched. The search words used to find these decisions included 'clinical guidelines', 'STGs' and 'medical practitioners are bound'. The type of STGs and the authority that they hold over the conduct of medical practitioners were analysed under these decisions by the courts in India.
| Results|| |
The search strategy identified 1695 results through PubMed and Google Scholar search. After removing the duplicates (n=225), the inclusion criteria were applied to 1470 publications that were searched manually. Fifty six full text articles were read from which 27 different STGs were selected [Figure 1].
|Figure 1: Search strategy and screening process. STGs, standard treatment guidelines.|
Click here to view
A total of 35 emails were sent to the authors, of whom 14 replied. Of these 14, two authors provided further information about six publications, three of which dealt with International STGs, one provided information about an STG already included in the study and two about STGs that were not on our list and were therefore, included in the study. While conducting a Google search for the STGs found in the publications, 34 STGs were found. Finally, 63 different STGs were included. Of these, only three were published in 2015 and 13 in 2014. The remaining 45 guidelines were published in 2012 or earlier. The oldest STG in the list was published in 1999 and was never revised after that. Two STGs did not mention the year of publication.
Forty eight STGs were for a single disease and the rest were for multiple conditions; 55 STGs did not include specific treatment according to levels of healthcare, one each had treatment specific for primary, secondary and tertiary levels of healthcare respectively, and six STGs were for all three levels of healthcare. None of the STGs were updated at regular intervals.
While analysing evidence base it was noted that of the 63 STGs, eight gave no references while 55 provided international and Indian references (partial Indian) [Figure 2]. There was no uniformity in the format regarding STGs in India. This was in contrast with clinical guidelines in the UK developed by NICE, which met all WHO recommendations. One of the reasons for this might be the fact that India has not yet put in place a systematic process for the development of STGs as NICE. The legal framework governing the development of STGs in India is described below, and compared with the process in the UK [Table 1].
|Figure 2: Number of standard treatment guidelines (STGs) fulfilling World Health Organization and authors' criteria.|
Click here to view
|Table 1: List of standard treatment guidelines (STGs) with details of year, edition, publication, authority and conditions included in the STGs|
Click here to view
Legal framework governing the development of STGs in India: The Clinical Establishments (Registration and Regulation) Act 2010 (Act) sets out conditions for the registration of clinical establishments. Although the Act itself does not contain a reference to STGs, clause (iii) of Rule 9 of the Clinical Establishments (Central Government) Rules 2012 (Rules) requires clinical establishments, as a condition of registration, to ensure compliance with such STGs as may be determined and issued by the Central and State Governments from time to time. Apart from this provision, however, the rules did not prescribe the procedure by which the STGs ought to be framed or the manner in which the power to develop these guidelines ought to be divided between the Central and State Governments. It was important to note that this provision in the Rules only empowered the Central and State Governments to frame STGs and to require compliance with them by clinical establishments as a condition of registration [Table 2]. However, the Clinical Establishments Act does not compel the States to develop STGs as it has been adopted only by a few States and Union Territories. This was in contrast to the UK, where section 237 of the Health and Social Care Act 2012 read with section 5 of the National Institute for Health and Care Excellence (Constitution and Functions) Regulations 2013 making it a function of NICE to give advice or guidance, provide information or make recommendations regarding any stuff associated with the provision of services under the National Health Service (NHS), public health services as well as social care in England. The Act and regulations additionally require NICE to establish procedures for giving such guidance, including a duty to consult persons if considered appropriate,. In furtherance of these provisions, NICE has developed an established procedure, the key details of which are briefly described below.
|Table 2: Comparison between legal authority for standard treatment guidelines in UK and India|
Click here to view
Documentation of the development process in the published Indian STGs was not available on Authority websites and in the STGs.
Development of NICE guidelines: At NICE, a Topic Selection-Oversight Group considers topics for guideline development and discusses their findings with the NHS and the Department of Health. Thereafter, the NHS and the Department of Health finalize the topic and make a referral for the development of clinical guidelines on the topic in question to NICE. After the topic for framing a guideline is identified, NICE commissions one of its specialist centres to frame a draft of the guideline on such topic. A number of stakeholders, such as manufacturers of medicines or devices related to the guideline topic, providers and commissioners of health services, national organizations representing patients and carers and/or healthcare professionals, statutory organizations, and research organizations that have formed countrywide recognized research connected to the guideline topic, are consulted throughout the development of each guideline. Subsequently, there is at least one public consultation on the draft of a guideline to gauge the comments of stakeholders registered with NICE. The guideline is then signed off for publication by the Guidance Executive of the NICE, following which steps are taken to communicate, disseminate and promote awareness about the guideline.
A number of other organizations such as the Guidelines and Audit Implementation Network (GAIN), the Royal Colleges and various professional organizations formulate clinical guidelines in England. While the clinical guidelines framed by NICE are nationally recognized, the ones framed by GAIN, or the Royal Colleges may be recognized and followed locally. There is nothing to suggest that gives precedence to NICE guidelines over those framed by other bodies. In any case, NICE inspects the clinical guidelines framed by other expert bodies as part of the process of developing its own guidelines. This inspection is helpful in determining the effectiveness of the existing clinical guidelines and practices, as well as in collating the opinion of expert bodies on the standardized treatments for various diseases and conditions.
While the clinical guidelines framed by NICE are not legally binding on medical practitioners and service providers, the courts are inclined to view such guidelines as a responsible body of medical opinion,,,. Consequently, practitioners and service providers, who do not adhere to such guidelines, are required to provide a reasonable explanation (which may be a counter medical opinion backed by credible sources) in order to discharge their burden of observing due diligence while exercising their functions.
STGs: United States of America:STGs or Clinical Practice Guidelines, as these are more commonly known in the USA are framed by a range of groups/organizations, most of which are made publicly available as resources through the website of the National Guideline Clearinghouse (NGC), set up by the Agency for Healthcare Research and Quality (AHRQ). The AHRQ, as its website (https://www.ahrq.gov/cpi/about/profile/index.html) states, is 'the lead Federal agency charged with improving the safety and quality of America's health care system.' A wide variety of organizations frame clinical practice guidelines in the US. According to the categories listed on the NGC website, these include academic institutions, disease-specific societies, federal government agencies, hospitals, independent expert panels, professional associations, non-profit organizations, as well as non-U.S. State/local government agencies. Some of these guidelines are rated according to the strength of their recommendations. For instance, ratings may vary from 1A to 2C, with a rating of 1A meaning 'strong recommendation, high-quality evidence', while a rating of 2C means 'weak recommendation, low-or-very-low-quality evidence'.
In 2011, a report titled 'Clinical Practice Guidelines we Can Trust' was published by the Institute of Medicine. This recommended eight standards that clinical practice guidelines ought to adhere to in order to considered trustworthy. The report also recommended that the AHRQ would need the NGC to 'provide a clear indication of the extent to which clinical practice guidelines submitted adhere to the standards for trustworthiness',.
| Discussion|| |
Development of STGs in India is done by multiple authorities like Central Government, State Government, Hospitals, professional associations and private organizations. This shows involvement and commitment by healthcare professionals, and Indian authorities regarding the improvement of healthcare of the population. Government has been developing STGs through the National Health Systems Resource Centre (NHSRC) and also as part of National Health Programme with the help of experts for fulfilling the need of the population.
Most of the STGs found in our study covered important sections in the STGs but key problems with STGs in India that our analysis revealed were-multiplicity, paucity of Indian evidence for guidelines, failure to periodically revise guidelines, failure to tailor them according to the level of healthcare, and finally, a lack of wide availability and accessibility. There were multiple STGs for the same conditions which were made by many authorities and professionals. For instance, there were six separate guidelines for diabetes. Multiplicity could be due to different purpose of development of the guidelines for insurance reimbursement, level of care and the scope of the guidelines. This duplication of efforts and time is avoidable by collaboration which will also save scarce resources, funds and experts' time.
There is a paucity of Indian research for the development of up to date STGs. Indian studies are particularly needed to answer specific research questions relevant to the Indian setting such as, cost of therapy, variation in dose, antimicrobial resistance. Evidence-based medicine has its own limitations as noted in many research articles but these limitations should not deter the authorities from making evidence-based guidelines.
None of the STGs mentioned any specific period after which they were revised. Only one STG was updated to a 3rd edition and six were in first or second editions. Utilization of recent systematic reviews and meta-analysis is important to get the highest quality data. Also, a locally produced STGs suing Indian data might improve acceptability than so-called imported/ international guidance.
Major obstacles reported in several studies in regular revisions of STGs were the availability of local expertise and a dearth of awareness of the concept and also prescribers' firmness on the inclusion of out-of-date practices, or of medications by brand names of untested efficacy. Additionally, it was observed that guidelines review groups often were short of time, interest, resources, and skills to collect and analyse every section of evidence, mainly in relation to editorial responsibilities.
Many States and authorities in India have been developing different STGs which are not available online. There is a need to ensure that STGs are made freely available online which could help in wider adoption in clinical practice.
Guidelines in India also have a contribution from the Industry, which could be a potential conflict of interest. As noted in a study by Sharma et al government and insurance companies using guidelines as a tool of a coercion to limit treatment choices (limiting medicine reimbursement), restraining independence of the practitioner, were perceived as a major barrier in the STG uptake by the physicians. Most respondents in this study did not appreciate the accountability protection offered by the guidelines, which was different from western country reports, where both these aspects (reimbursement limitations and liability perception) act as enablers for STGs.
One of the solutions to the multiplicity of STGs might be to designate a specific authority with the task of developing STGs, preferably by imposing a statutory duty. This duty could be accompanied by enabling rules and regulations describing the procedure for developing STGs, the information that they ought to contain, and methods of dissemination, along the lines of the procedure followed by NICE. This procedure ought to incorporate the requirement of periodic updating. A good quality STG could include points as mentioned in The international Appraisal of Guidelines, Research and Evaluation (AGREE) II checklist.
A particularly useful approach to adopt from NICE is making available evidence summaries for unlicensed or off-label medicines. These summaries critically review the strengths and weaknesses of such medicines, but do not constitute formal NICE guidance. STGs that provide physicians with details about the use of off-label medicines would be especially useful for paediatric treatment in India, where there is already widespread off-label use of drugs.
When Indian STGs are compared to NICE guidelines, they fall short in many points. NICE guidelines are updated many times every few years depending on the condition, year of revision and revised points are mentioned clearly, diagnostic criteria and drug/ treatment of choice are given, and it is evidence-based with appropriate scientific references mentioned. In USA, there are multiple agencies which frame the STGs and these are grounded on evidence which are of high-quality with level of evidence and class of recommendations mentioned in most of the guidelines. But just like NICE guidelines, STGs in the USA do not mention points about the cost of treatment. Level of healthcare in the STGs is a unique feature to Indian STGs and this does not find a place in NICE guidelines and USA STGs.
Among the major limitations, STGs are often not published in peer-reviewed scientific journals and are often not available online. The process of developing STGs (except the use of evidence base) was not evaluated as this information was not uniformly available.
India demonstrates great regional variation in disease prevalence as well as the kinds of healthcare providers settings and prescribers. The present analysis while appreciating the STGs developed by the government, individuals and professional organizations in India, demonstrated the need for a collaborative and coordinated approach to STG development, with robust consultative mechanisms, sensitivity to local conditions and easy accessibility. An important first step in this regard would be to provide details of well-defined procedures.
Financial support & sponsorship: None.
Conflicts of Interest: None.
| References|| |
Sharma S, Sethi GR, Gupta U, Chaudhury RR. Barriers and facilitators to development of standard treatment guidelines in India. WHO South East Asia J Public Health
Holloway K, Carandang E, Hogerzeil H, Laing R, Lee D, Chalker J, et al. Drug and therapeutics committees: A practical guide
. Geneva, Switzerland: World Health Organization; 2003. Available from: http://apps.who.int/medicinedocs/pdf/s4882e/s4882e.pdf
, accessed on May 23, 2017.
Janmejaya S. Behavior of health workers toward the implementation of clinical guidelines. Health Res Rev
Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med
The National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations. England: National Health Service; 2013. Available from: http://www.legislation.gov.uk/uksi/2013/259/made
, accessed on May 24, 2017.
Kumar L. Consensus guidelines on management of childhood asthma in India. Indian Pediatr
Jindal SK, Gupta D, Aggarwal AN, Agarwal R; World Health Organization, Government of India. Guidelines for management of asthma at primary and secondary levels of health care in India (2005). Indian J Chest Dis Allied Sci
Rai SP, Patil AP, Vardhan V, Marwah V, Pethe M, Pandey IM, et al.
Best treatment guidelines for bronchial asthma. Med J Armed Forces India
Agarwal R, Dhooria S, Aggarwal AN, Maturu VN, Sehgal IS, Muthu V, et al.
Guidelines for diagnosis and management of bronchial asthma: Joint ICS/NCCP (I) recommendations. Lung India
ICMR. Guidelines for Management of Type 2 Diabetes. Available from: http://icmr.nic.in/guidelines_diabetes/guide_diabetes.htm
, accessed on May 23, 2017.
Sahay BK. API-ICP Guidelines on Diabetes 2007. J Assoc Physicians India
Indian National Consensus Group. Premix insulin: Initiation and continuation guidelines for management of diabetes in primary care. J Assoc Phys India
Expert Committee on Pediatric Epilepsy, Indian Academy of Pediatrics. Guidelines for diagnosis and management of childhood epilepsy. Indian Pediatr
Prasad K, Kaul S, Padma MV, Gorthi SP, Khurana D, Bakshi A, et al.
Stroke management. Ann Indian Acad Neurol
Ravishankar K, Chakravarty A, Chowdhury D, Shukla R, Singh S. Guidelines on the diagnosis and the current management of headache and related disorders. Ann Indian Acad Neurol
Mishra D, Sharma S, Sankhyan N, Konanki R, Kamate M, Kanhere S, et al.
Consensus guidelines on management of childhood convulsive status epilepticus. Indian Pediatr
Mahadevan S, Ingrid J. National snakebite management protocol (India), 2008 (Shortened version). Indian J Emerg Pediatr
All India Ophthalmological Society, & Cipla. AIOS Guidelines to Prevent Intraocular Infection. India: All India Ophthalmological Society, & Cipla; 2009. Available from: http://www.aios.org/guidelinesendoph.pdf
, accessed on December 29, 2017.
Krishnamurthy V, Sharma A, Aggarwal A, Kumar U, Amin S, Rao UR, et al.
Indian rheumatology association guidelines for management of glucocorticoid-induced osteoporosis. Endorsed by: Endocrine Society of India and Indian Society for Bone & Mineral Research. Indian J Rheumatol
Ramakrishna BS, Makharia GK, Abraham P, Ghoshal UC, Jayanthi V, Agarwal BK, et al.
Indian society of gastroenterology consensus on ulcerative colitis. Indian J Gastroenterol
Shah SN, Billimoria AR, Mukherjee S, Kamath SA, Munjal YP, Maiya M, et al
. Special issue on indian guidelines on hypertension (I.G.H.)-III. J Assoc Phys India
Bhatia V, Bavdekar A, Matthai J, Waikar Y, Sibal A. Management of neonatal cholestasis: Consensus statement of the pediatric gastroenterology chapter of Indian academy of pediatrics. Indian Pediatr
Parikh P, Patil V, Agarwal JP, Chaturvedi P, Vaidya A, Rathod S, et al.
Guidelines for treatment of recurrent or metastatic head and neck cancer. Indian J Cancer
Gupta D, Agarwal R, Aggarwal AN, Maturu VN, Dhooria S, Prasad KT, et al.
Guidelines for diagnosis and management of chronic obstructive pulmonary disease: Joint Recommendations of Indian Chest Society and National College of Chest Physicians (India). Indian J Chest Dis Allied Sci
Bhatnagar S, Lodha R, Choudhury P, Sachdev HP, Shah N, Narayan S, et al.
IAP guidelines 2006 on management of acute diarrhea. Indian Pediatr
Unnikrishnan AG, Kalra S, Baruah M, Nair G, Nair V, Bantwal G, et al.
Endocrine society of india management guidelines for patients with thyroid nodules: A position statement. Indian J Endocrinol Metab
Indian Society of Pediatric Nephrology. Revised Statement on Management of Urinary Tract Infections. Available from: http://medind.nic.in/ibv/t11/i9/ibvt11i9p709.pdf
, accessed on May 24, 2017.
Gupta D, Agarwal R, Aggarwal AN, Singh N, Mishra N, Khilnani GC, et al.
Guidelines for diagnosis and management of community- and hospital-acquired pneumonia in adults: Joint ICS/NCCP(I) recommendations. Lung India
Puri P, Anand AC, Saraswat VA, Acharya SK, Sarin SK, Dhiman RK, et al.
Consensus statement of HCV task force of the Indian national association for study of the liver (INASL). Part II: INASL recommendations for management of HCV in India. J Clin Exp Hepatol
Standard Treatment Guidelines for Medical Officers. State Heal Resour Cent. Government of Chhattisgarh, Department of Health & Family Welfare; 2003. Available from: http://www.cspc.in/dic/pdf/cg_stg.pdf
, accessed on May 23, 2017.
Samanta A, Samanta J, Gunn M. Legal considerations of clinical guidelines: Will NICE make a difference? J R Soc Med
Hurwitz B. Legal and political considerations of clinical practice guidelines. BMJ
Hurwitz B. How does evidence based guidance influence determinations of medical negligence? BMJ
Fearnley RA, Bell MD, Bodenham AR. Status of national guidelines in dictating individual clinical practice and defining negligence. Br J Anaesth
Institute of Medicine. Graham R, Mancher M, Wolman DM, Greenfield S, Steinberg E, editor(s). Clinical practice guidelines we can trust
. Washington (DC): National Academies Press, 2011.
Graham R, Mancher M, Miller Wolman D, Greenfield S, Steinberg E; Institute of Medicine (US) Committee on Standards for Developing Trustworthy Clinical Practice Guidelines. Clinical Practice Guidelines We Can Trust. Washington (DC): National Academies Press (US); 2011. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24983061
, accessed on May 24, 2017.
Heneghan C, Mahtani KR, Goldacre B, Godlee F, Macdonald H, Jarvies D, et al.
Evidence based medicine manifesto for better healthcare. BMJ
Sharma S, Pandit A, Tabassum F. Potential facilitators and barriers to adopting standard treatment guidelines in clinical practice. Int J Health Care Qual Assur
Brouwers MC, Kerkvliet K, Spithoff K; AGREE Next Steps Consortium. The AGREE reporting checklist: A tool to improve reporting of clinical practice guidelines. BMJ
Mir AN, Geer MI. OFF-LABEL USE OF MEDICINES IN CHILDREN. Int J Pharm Sci Res
Garrison LP. Cost-Effectiveness and Clinical Practice Guidelines: Have We Reached a Tipping Point?-An Overview. Value Health
[Figure 1], [Figure 2]
[Table 1], [Table 2]